이소구연산 탈수소효소(IDH) 억제제 시장 : 세계 예측(2026-2032년)

The Isocitrate Dehydrogenase Inhibitors Market is projected to grow by USD 5.09 billion at a CAGR of 13.24% by 2032.

Isocitrate dehydrogenase inhibitors are targeted medicines designed to suppress abnormal IDH1 or IDH2 enzyme activity caused by specific mutations. Their clinical relevance is established in selected hematologic malignancies and is being evaluated in additional tumor settings. The market is shaped by biomarker-based diagnosis, mutation-specific treatment selection, regulatory evidence requirements, companion diagnostics, and the need to position therapy within evolving care pathways.

Precision Oncology Is Reshaping IDH Inhibitor Use

The landscape is shifting from broad cytotoxic treatment toward molecularly defined care. IDH mutation testing increasingly influences eligibility, treatment sequencing, and clinical-trial enrollment, while real-world practice must address resistance, relapse, tolerability, drug interactions, and differences between newly diagnosed and relapsed disease. Adoption also depends on the integration of oral treatment, specialist prescribing, diagnostic access, reimbursement rules, and clinical guideline updates.

Artificial Intelligence Strengthens Biomarker and Treatment Decisions

Artificial intelligence can support this field by improving interpretation of genomic and clinical data, identifying patients likely to benefit from IDH-directed therapy, and helping researchers prioritize combinations and resistance mechanisms. Machine-learning tools may also assist image analysis, safety monitoring, trial recruitment, and longitudinal outcome assessment. Their value depends on validated datasets, transparent performance, appropriate clinical oversight, protection of patient data, and confirmation that algorithmic outputs improve rather than replace expert judgment.

Regional Insights Across Six Healthcare Landscapes

North America benefits from advanced oncology centers, established molecular diagnostics, and active clinical research, although reimbursement variation and treatment access remain important considerations. Europe combines strong academic infrastructure with country-level differences in health-technology assessment, diagnostic pathways, and funding. Asia-Pacific presents expanding precision-oncology capacity alongside uneven access to sequencing, specialist expertise, and innovative medicines. Latin America is influenced by diagnostic infrastructure, public-sector procurement, and affordability constraints. The Middle East is developing specialized cancer services and genomic capabilities, with access varying across health systems. Africa faces substantial disparities in pathology, molecular testing, oncology workforce capacity, and treatment availability, making diagnostic strengthening central to progress.

Group Insights Reveal Different Policy and Access Priorities

ASEAN countries are pursuing oncology modernization at different speeds, with molecular testing capacity and reimbursement creating meaningful variation. BRICS economies combine significant research and manufacturing capabilities with uneven access across regions and income groups. The European Union benefits from collaborative scientific and regulatory structures but retains national differences in assessment and financing. G7 members generally possess mature oncology infrastructure, while affordability and equitable access remain policy concerns. GCC states are investing in specialized care and genomic medicine, with coordinated procurement and workforce development supporting implementation. NATO members span diverse health systems, so shared research capacity does not eliminate differences in diagnosis, reimbursement, or clinical uptake.

Country-Level Conditions Affect Diagnosis and Treatment Integration

The United States and Canada have strong specialist networks and molecular oncology capabilities, with access shaped by payer policy and provincial or state-level systems. Germany, France, Italy, Spain, and the United Kingdom combine sophisticated cancer services with distinct regulatory, assessment, and reimbursement processes. Australia has advanced clinical research and centralized public-health structures, but geographic access remains relevant. Japan and South Korea support high-quality oncology and diagnostic infrastructure, with national approval and coverage pathways influencing use. China is expanding precision medicine and domestic research capacity while navigating regional variation. India faces major differences between metropolitan and rural oncology access. Brazil and Mexico are strengthening cancer services but continue to encounter diagnostic and financing disparities. Russia has substantial scientific expertise, while access and care delivery may vary by region. Across all countries, reliable mutation testing and coordinated multidisciplinary care are foundational.

Priorities for Leaders in Precision Oncology

Industry leaders should align clinical development with clearly defined IDH-mutated populations, clinically meaningful endpoints, and evidence that reflects routine practice. Diagnostic partnerships should support accurate, timely, and affordable mutation testing rather than treating testing as a secondary activity. Organizations should prepare for resistance through translational research and rational combination strategies, while maintaining rigorous safety surveillance and interaction management. Access planning should address reimbursement evidence, specialist education, patient support, and regional diagnostic gaps. Responsible use of artificial intelligence requires prospective validation, governance, cybersecurity, bias monitoring, and human accountability. Cross-sector collaboration among clinicians, laboratories, regulators, and patient groups can improve implementation and evidence quality.

Research Methodology for the Executive Summary

This summary uses the supplied market definition-Isocitrate Dehydrogenase Inhibitors-and synthesizes established scientific and clinical principles concerning IDH1 and IDH2 biology, biomarker testing, oncology care delivery, regulation, and access. Regional, group, and country observations are qualitative and based on publicly recognized differences in healthcare infrastructure, diagnostic capacity, research activity, and policy environments. No market estimates, market shares, forecasts, or company-specific claims are included. Interpretation should be complemented by current clinical guidelines, regulatory documents, peer-reviewed evidence, and local reimbursement requirements.

Conclusion: Biomarker Precision and Access Will Define Progress

The future of isocitrate dehydrogenase inhibitors depends on more than demonstrating enzyme inhibition. Durable clinical value will require accurate mutation identification, appropriate treatment sequencing, management of resistance and toxicity, dependable diagnostics, and equitable integration into oncology systems. Regional and national differences make implementation strategies essential, while artificial intelligence offers supportive capabilities only when validated and governed responsibly. Leaders that connect therapeutic evidence with diagnostics, patient access, and real-world outcomes will be best positioned to advance IDH-directed care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Isocitrate Dehydrogenase Inhibitors Market, by Type

• 7.1. Introduction
• 7.2. Mutant Idh1 Inhibitors
• 7.3. Mutant Idh2 Inhibitors
• 7.4. Pan-Idh Inhibitors

8. Isocitrate Dehydrogenase Inhibitors Market, by Indication

• 8.1. Introduction
• 8.2. Acute Myeloid Leukemia
• 8.3. Cholangiocarcinoma
• 8.4. Glioma

9. Isocitrate Dehydrogenase Inhibitors Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral

10. Isocitrate Dehydrogenase Inhibitors Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Channel
• 10.4. Retail Pharmacy

11. Isocitrate Dehydrogenase Inhibitors Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Clinics
• 11.4. Hospitals

12. Isocitrate Dehydrogenase Inhibitors Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Isocitrate Dehydrogenase Inhibitors Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Isocitrate Dehydrogenase Inhibitors Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agios Pharmaceuticals, Inc.
• 16.2. Aslan Pharmaceuticals
• 16.3. Bayer Aktiengesellschaft
• 16.4. Bristol-Myers Squibb Company
• 16.5. Celgene Corporation
• 16.6. CStone Pharmaceuticals
• 16.7. Daiichi Sankyo Company, Limited
• 16.8. Forma Therapeutics, Inc.
• 16.9. HUTCHMED Limited
• 16.10. Kura Oncology, Inc.
• 16.11. Les Laboratoires Servier
• 16.12. Merck & Co., Inc.
• 16.13. Novartis AG
• 16.14. Ohm Oncology
• 16.15. Pfizer, Inc.
• 16.16. Philogen S.p.A.
• 16.17. Rigel Pharmaceuticals, Inc.
• 16.18. Roche Holding AG
• 16.19. Taiho Pharmaceutical Co., Ltd.
• 16.20. Tragara BioSciences, Inc.

17. Key Experts